ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Cempra, Inc." (CEMP) Report Updated: Dec 22, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Cempra, Inc." (CEMP)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Pharmaceuticals
Competitors: ANIP, SCLN, HSP, TEVA

Stock Analysis

Rating: Monthly View

A
B
C
D
F
December January February March April May June July August September October November

Rating: Weekly View

This Week: B down no change
Last Week: B same upgrade
Two Weeks Ago: C up no change
service keys

"Cempra, Inc."© quotemedia

Company Profile

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics for the treatment of infectious diseases. The company provides Solithromycin, an oral and intravenous fluoroketolide for the treatment of community acquired bacterial pneumonia; and Taksta, an oral therapy for the treatment of prosthetic joint, and acute bacterial skin and skin structure infections. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.

Recent News: "Cempra, Inc."